Search results.

Check exact active ingredient, molecular class, brand, FDA application, approved use, dosage form, label company, and current primary regulatory records.

FDA-approved non-peptide GLP-1 comparator. Film-coated tablets · Oral. NDA 220934 · FDA-approved prescription drug.

Separate Foundayo's official $649 list price from current self-pay prices by strength, commercial-insurance savings, eligibility limits, and the actual pharmacy result.

Compare 5 exact-size GHK-Cu research listings, including 3 confirmed in-stock rows, the $44.99 current low, and 3 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 1 compound-specific country findings.

Audit the accepted GHK-Cu 100 mg price change from $60.99 to $67.09, plus current matched-market range, availability, sources, and methodology.

Compare 3 exact-size IGF-1 LR3 research listings, including 1 confirmed in-stock rows, the $27.00 current low, and 1 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 0 compound-specific country findings.

Compare 3 exact-size Ipamorelin research listings, including 3 confirmed in-stock rows, the $54.99 current low, and 2 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 2 compound-specific country findings.

Separate ipamorelin identity, short-term growth-hormone response, two completed Phase 2 records, FDA safety concerns, unsupported wellness claims, and worldwide verification routes.

Audit the accepted Ipamorelin 10 mg price change from $54.99 to $60.49, plus current matched-market range, availability, sources, and methodology.

Ipamorelin and CJC-1295 no-DAC appear together across many research-catalog searches, but they are not the same seller-labelled material and their published boards use different nominal vial sizes. This page compares current price footprints, vendor overlap, availability, and evidence access while keeping identity and unit boundaries explicit.

Explain why FDA-approved Foundayo activates the GLP-1 receptor but orforglipron is a non-peptide small molecule, then compare it with Wegovy, Zepbound, and retatrutide.

Compare 3 exact-size Kisspeptin-10 research listings, including 2 confirmed in-stock rows, the $37.00 current low, and 2 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 0 compound-specific country findings.

Separate KPV identity, cell and animal findings, ex vivo skin research, missing human administration data, current FDA compounding review, and worldwide verification routes.

Obesity and metabolic pipeline. GLP-1 receptor agonist + GIP receptor antagonist · Subcutaneous injection. 27 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

MariTide and CagriSema are different investigational obesity programs with no head-to-head trial. MariTide is Amgen's peptide-antibody conjugate that activates GLP-1 receptors and antagonizes GIP receptors, with monthly dosing at the center of its efficacy program. CagriSema is Novo Nordisk's once-weekly combination of cagrilintide and semaglutide, engaging amylin and GLP-1 pathways. CagriSema has completed pivotal Phase 3 trials and is under FDA review. MariTide has Phase 2 efficacy evidence and an active Phase 3 program. Neither is FDA approved.

MariTide and retatrutide are different investigational obesity programs with no head-to-head trial. MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in a long-acting peptide-antibody conjugate, while retatrutide activates GIP, GLP-1, and glucagon receptors in one molecule. MariTide has a monthly Phase 2 efficacy record and an active Phase 3 program. Retatrutide is a once-weekly program with Phase 3 topline results. Neither is FDA approved, and their headline percentages cannot establish which is more effective.

MariTide and amycretin, now called zenagamtide, are separate investigational obesity programs designed around different mechanisms and treatment schedules. MariTide is a peptide-antibody conjugate that activates GLP-1 receptors and antagonizes GIP receptors, with monthly dosing at the center of its efficacy program. Zenagamtide activates GLP-1 and amylin receptors and is being developed as a daily tablet and weekly injection. No head-to-head trial has compared them, and neither is FDA approved.

Obesity and metabolic pipeline. GLP-1 and glucagon receptor dual agonist · Once-weekly subcutaneous injection. 37 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Mazdutide and retatrutide are different once-weekly peptide drugs with no head-to-head trial. Mazdutide activates GLP-1 and glucagon receptors and has Chinese approvals for chronic weight management and type 2 diabetes. Retatrutide also activates the GIP receptor and remains investigational, with Phase 3 obesity results but no marketing approval. Neither drug is FDA approved. Mazdutide's China approval does not create approval or legitimate supply in the United States or another country, and separate Phase 3 percentages cannot determine which drug is more effective, safer, or more appropriate for an individual.

Mazdutide and survodutide are separate once-weekly GLP-1 and glucagon receptor dual agonists, and no head-to-head trial has compared them. Mazdutide has Chinese approvals for chronic weight management and type 2 diabetes, while survodutide remains investigational and has reported Phase 3 obesity results plus a dedicated liver-disease program. Neither drug is FDA approved. Their shared receptor class does not make the molecules interchangeable, and results from GLORY and SYNCHRONIZE cannot establish which program is more effective, safer, or better for an individual.

Compare 3 exact-size Melanotan I research listings, including 2 confirmed in-stock rows, the $29.99 current low, and 1 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 0 compound-specific country findings.

Melanotan I and Melanotan II are easy to confuse in search results, abbreviations, and seller menus. This comparison resolves the exact seller-labelled identity first, then shows the current 10 mg US research-listing footprint, vendor overlap, public-document access, availability, and price dispersion for each separate board.

Compare 3 exact-size Melanotan II research listings, including 1 confirmed in-stock rows, the $36.99 current low, and 1 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 4 compound-specific country findings.

Audit Melanotan II pigmentation and erectile-function studies, reported side effects, serious case reports, FDA status, Scenesse and Vyleesi identity boundaries, current prices, and worldwide rules.

Compare 7 exact-size MOTS-c research listings, including 5 confirmed in-stock rows, the $37.00 current low, and 4 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 1 compound-specific country findings.

Separate MOTS-c mouse and biomarker research from the new recruiting 120-participant Phase 2a trial, then check weight-loss claims, side effects, FDA status, prices, and global routes.

Audit the accepted MOTS-c 10 mg price change from $44.99 to $49.49, plus current matched-market range, availability, sources, and methodology.

Compare 4 exact-size NAD+ research listings, including 3 confirmed in-stock rows, the $69.99 current low, and 2 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 0 compound-specific country findings.

Audit the accepted NAD+ 1000 mg price change from $117.99 to $129.79, plus current matched-market range, availability, sources, and methodology.

Orforglipron and retatrutide both engage the GLP-1 receptor, but they are fundamentally different drugs with no head-to-head trial. Orforglipron is a non-peptide small molecule and the active ingredient in the FDA-approved oral product FOUNDAYO. Retatrutide is an investigational synthetic peptide that activates GIP, GLP-1, and glucagon receptors and is being studied as a weekly injection. FOUNDAYO has an approved US label and pharmacy product record. Retatrutide has Phase 3 obesity results but no marketing approval. The larger retatrutide percentage came from a different trial, duration, regimen, and estimand, so it cannot establish superiority over orforglipron.

Foundayo and Wegovy are FDA-approved US weight-management products that activate the GLP-1 receptor, but they are not the same kind of drug and have not been compared in a randomized head-to-head trial. Foundayo contains orforglipron, a once-daily non-peptide small-molecule tablet. Wegovy contains the peptide semaglutide and its current US label includes both a once-daily 25 mg tablet and once-weekly injections. The Foundayo label reports about 11.1% mean weight reduction at 72 weeks for its highest approved equivalent-dose group, while the Wegovy tablet label reports 13.6% at 64 weeks. Those values come from separate protocols and do not prove that either product is superior.

Foundayo and Zepbound are FDA-approved US products for defined adult weight-management populations, but they differ in molecule, mechanism, route, schedule, labeled uses, and evidence. Foundayo contains the non-peptide small molecule orforglipron, activates the GLP-1 receptor, and is taken as a once-daily tablet. Zepbound contains the peptide tirzepatide, activates GIP and GLP-1 receptors, and is injected once weekly. Their labels report results from separate 72-week studies, not a randomized comparison. Foundayo's highest approved equivalent-dose group averaged about 11.1% weight reduction, while Zepbound Study 1 reported up to 20.9%. That cross-trial difference does not establish a winner.

Obesity and metabolic pipeline. Balanced 1:1 GLP-1 and glucagon receptor dual agonist · Once-weekly subcutaneous injection. 9 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Pemvidutide and retatrutide are different investigational once-weekly peptides with no head-to-head trial. Pemvidutide activates GLP-1 and glucagon receptors in a balanced dual-agonist design and is currently focused on MASH and alcohol-related liver conditions after a completed Phase 2 obesity study. Retatrutide activates GIP, GLP-1, and glucagon receptors and has reported Phase 3 obesity results. Neither is FDA approved. Retatrutide's larger and longer Phase 3 headline cannot establish that it is better for MASH, liver outcomes, safety, or an individual, while pemvidutide's FDA designations do not establish approval or comparative superiority.

Pemvidutide and survodutide are separate investigational once-weekly GLP-1/glucagon dual agonists with no head-to-head trial. Pemvidutide has a completed Phase 2 obesity study, a completed Phase 2b MASH study, and a planned MASH Phase 3 program. Survodutide has an active Phase 3 program with reported 76-week obesity results and liver-focused studies. Neither is approved for marketing. Their receptor labels overlap, but the molecules, development priorities, doses, populations, durations, efficacy analyses, and gastrointestinal discontinuation records differ, so they are not interchangeable and the available percentages cannot name a winner.

Download 268 deduplicated registry records with named programs, status, phase, enrollment, completion dates, results availability, 53 countries, 1,840 recruiting cities, postal areas, registry geocoordinates, and direct NCT sources.